12:00 AM
Mar 05, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Cinryze regulatory update

ViroPharma disclosed in its 4Q11 earnings call that in early April it will submit a response to FDA's complete response letter regarding industrial scale manufacturing expansion activities for hereditary angioedema (HAE) drug Cinryze. The company anticipates a 4-month review, with a decision expected in early August....

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >